ArticleScientific reports2026
Glycoconjugate strategy for GLUT-driven curcumin delivery and anticancer activity in breast cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective targeting of cancer cells is a critical strategy in anticancer therapy, and the overexpression of glucose transporters (GLUTs) in malignant cells provides an attractive avenue for achieving this selectivity. In this study, we report the synthesis and biological evaluation of glycoconjugate vanadyl complexes as GLUT-directed anticancer agents against breast cancer. A Schiff base ligand (CG) was synthesized through the condensation of curcumin (C) and glucosamine (G), followed by complexation with vanadyl to form [VO(CG)₂]·5H₂O. The synthesized compounds were comprehensively characterized by elemental analysis, MS, NMR, FT-IR, TGA, molar conductance, and magnetic susceptibility measurements. Spectroscopic and computational studies confirmed that the ligand coordinates in a bidentate chelating mode via the azomethine nitrogen and the enolic oxygen. Biological evaluation in MCF-7 breast cancer cells included cytotoxicity assays, molecular docking, DNA-binding studies, and quantitative gene expression analysis. Both compounds exhibited cytotoxic activity, with the CG ligand showing the highest potency (IC₅₀ = 7.51 ± 0.12 μg/mL or 14.2 μM). Notably, co-treatment with the GLUT inhibitor quercetin significantly increased the IC₅₀ value, suggesting the involvement of GLUT-mediated cellular uptake. Molecular docking studies indicated favorable binding affinity toward GLUT, while DNA-binding experiments demonstrated interaction with DNA. Treatment of MCF-7 cells with the glycoconjugate ligand induced DNA damage, modulated the expression of cell cycle- and apoptosis-related genes, and promoted apoptosis. Flow cytometric analysis demonstrated that the glycoconjugate significantly arrested MCF-7 cells in the S-phase (49.40% vs 22.22% in control). This finding is consistent with impaired cell cycle progression and may be associated with the observed DNA interaction. Quantitative real-time PCR analysis of the CG compound revealed significant upregulation of BAX and CDKN1A (p21) (p ≤ 0.05) and pronounced upregulation of STK11 (LKB1) (p ≤ 0.001), suggesting activation of the AMPK signaling pathway and a metabolic stress response. Overall, the glycoconjugate ligand induces apoptosis and cell cycle arrest through oxidative and metabolic stress mediated by AMPK-STK11 signaling, highlighting its potential as a GLUT-targeted chemotherapeutic agent for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.